BioCentury
ARTICLE | Financial News

Gene therapy play Bamboo raises $49.5M

February 13, 2016 2:58 AM UTC

Bamboo Therapeutics Inc. (Chapel Hill, N.C) raised $49.5 million in a series A round. Bamboo Co-Founder and CEO Sheila Mikhail declined to name any of the investors except CureDuchenne Ventures LLC, whose investment was announced last month. CureDuchenne told BioCentury it invested $1.5 million.

Bamboo has recombinant adeno-associated virus (rAAV) technology developed by Co-Founder, Chairman and CSO Jude Samulski, who is the director of the University of North Carolina Gene Therapy Center. Bamboo also has chimeric AAV, self-complementary and dual glycan receptor AAV technologies. According to Bamboo's website, the vectors have been engineered to improve delivery to some tissues while avoiding other tissues. ...